Alpha Omega Wealth Management buys $2,992,671 stake in Pfizer (PFE)

Pfizer (PFE) : Alpha Omega Wealth Management scooped up 205 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 85,140 shares of Pfizer which is valued at $2,992,671.Pfizer makes up approximately 2.44% of Alpha Omega Wealth Management’s portfolio.

Other Hedge Funds, Including , Athena Global Investors reduced its stake in PFE by selling 30,694 shares or 33.11% in the most recent quarter. The Hedge Fund company now holds 62,002 shares of PFE which is valued at $2,179,370. Pfizer makes up approx 3.26% of Athena Global Investors’s portfolio.Gabelli Funds reduced its stake in PFE by selling 371,000 shares or 21.8% in the most recent quarter. The Hedge Fund company now holds 1,331,123 shares of PFE which is valued at $47,174,999. Pfizer makes up approx 0.28% of Gabelli Funds’s portfolio.Prospera Financial Services Inc boosted its stake in PFE in the latest quarter, The investment management firm added 2,423 additional shares and now holds a total of 25,905 shares of Pfizer which is valued at $954,599. Pfizer makes up approx 0.19% of Prospera Financial Services Inc’s portfolio.Daiwa Securities Group boosted its stake in PFE in the latest quarter, The investment management firm added 70,900 additional shares and now holds a total of 808,121 shares of Pfizer which is valued at $29,779,259. Pfizer makes up approx 0.18% of Daiwa Securities Group’s portfolio.Cabot Wealth Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 8,515 shares of Pfizer which is valued at $309,180. Pfizer makes up approx 0.08% of Cabot Wealth Management Inc’s portfolio.

Pfizer opened for trading at $35.05 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.37% or 0.13 points. The heightened volatility saw the trading volume jump to 1,23,54,034 shares. Company has a market cap of $212,965 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.